



[Dr David Moore](#) » [News](#) » [Does low dose aspirin reduce the risk of miscarriage?](#)



[Does low dose aspirin reduce the risk of miscarriage?](#)



By [Dr David Moore](#), 3 April 2014

According to [an RCT published in The Lancet this week](#) -maybe...

Low-dose (75-100mg) daily aspirin ("LDA"), commenced before 16 weeks, has been shown in high-powered studies to reduce outcomes such as pre-eclampsia, fetal growth restriction, and preterm birth. The effect is strongest in high-risk women (women with events in previous pregnancies; see Villa *et al*, BJOG 2013 and Roberge *et al* Ultrasound O&G 2013). As often happens, we become tempted to prescribe these *proven* therapies for indications in which they are *unproven*. Recurrent miscarriage (three or more consecutive pregnancies ending in miscarriage before 20 weeks) causes immeasurable anguish to couples, and mitigating against future pregnancy loss. Interestingly, LDA coupled with low dose heparin has been shown to reduce the risk of miscarriage in women with RPL *who also have antiphospholipid syndrome*, whereas this recipe has no effect in women with RPL in the absence of APS (Cochrane 2009).

The use of LDA in women *without* RPL (that is, one or two miscarriages only) has found mixed results with small, unpowered studies. The most recent, large, placebo-controlled RCT (dubbed the "EAGeR study") sought to scrutinise this relationship more closely: randomised such women on LDA before conception, and found no improvement in livebirth or miscarriage rates for women who had *not* had a previous miscarriage. They concluded that routine LDA should not be used in this group. Interestingly, however, their data *did* reveal a statistically significant increase in livebirth rates in a group of women who had one previous miscarriage, before 20 weeks, within the last year. Hmm... perhaps it's a statistical anomaly ("Lies, damned lies, and statistics"), but certainly that little chestnut requires more research into causes, and there's no biologically plausible way that aspirin would improve many of them (such as chromosomal problems).

So, bottom line, LDA shouldn't be used indiscriminately with the hope of improving livebirth rates - we have good evidence of benefit, and quality evidence to refute benefit in other populations. This study adds to this knowledge.

PS- I often get raised eyebrows when discussing aspirin use in pregnancy ("isn't that harmful?") - there is extensive evidence that aspirin is *suitably prescribed* in pregnancy (James *et al* O&G Survey 2008).

About Dr David Moore



David is a Fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, and a Fellow of the Royal College of Obstetricians and Gynaecologists, Queensland. He is highly skilled in the management of complex and high-risk pregnancies, and has specialised experience in the management of endometriosis, pelvic floor and incontinence surgery. David has completed a Master of Reproductive Medicine, and has extensive experience in the management of fertility problems, and can offer the full range of assisted reproductive treatments. He is a Lecturer at the Queensland Medical School, and has published both medical journal and textbook contributions.

[« Are babies who are "turned" by ECV still more likely to be born by caesarean section?](#)

[Back to News](#)

[Excision:](#)

